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Polygalasaponins are the major active constituents of Polygala tenuifolia exhibiting antiamnesic activity, but their applications are
limited due to their toxicities. Evidence showed that the toxicities can be attenuated by hydrolysis. Herein, effects of a hydrolysate
of polygalasaponins (HPS) on cognitive impairment induced by Aβ25−35 were assessed by Morris water maze and step-through
passive avoidance tests. The impaired spatial reference memory was improved by HPS (50 and 100mg/kg). In the acquisition trial
of step-through test, HPS (50 and 100mg/kg) increased the latency into the dark chamber and decreased the error frequency
significantly (P < .05). However, no significant change was observed during the retention trial. Additionally, HPS increased the
corresponding SOD activities (62.34%, 22.09%) and decreased MDA levels (28.21%, 32.35%) in both cortex and hippocampus as
compared to model animals. These results show that HPS may be a useful treatment against amnesia probably via its antioxidant
properties.
1. Introduction
With global increases in population and life expectancy,
Alzheimer’s disease (AD), a neurodegenerative disorder
characterized by progressive memory loss and cognitive
deterioration, has become a major health problem [1].
Despite the fact that more than 35 million people will be
suffering from AD by 2010, there are only few treatment
options available [2]. Thus a search for novel pharma-
cotherapies especially from traditional medicines for AD has
recently been the focus of many researchers.
Polygala tenuifolia (called “Yuanzhi” in Chinese) has been
widely used as a memory enhancer for people in Asian
countries for many years [3–5], and it is also included
in many traditional prescriptions used for treatment of
amnesia and dementia [6–10]. Recently, preclinical trials
showed that ethanol extracts of P. tenuifolia possess memory-
enhancing effects in healthy [11] and elderly volunteers [12].
There is a growing support for improvement of memory
function in many animal models with learning and memory
impairment induced chemically or physically, for example,
by scopolamine [13–15], KCN [13], stress [16], and hypoxia
[17]. Additionally, it is also effective on aging [14, 18] and
on senescence-accelerated prone (SAMP8) mice [19]. This
cognitive improvement by P. tenuifolia has been associated
with polygalasaponins as its main constituents [13–15].
However, it has been reported that the polygala saponin
fraction was highly toxic in animals [20, 21], and even
caused death to SD rats (0.5mg/kg, i.p.) [22] and ICR mice
(100mg/kg, p.o.) [13], which seriously limits the application
and development of an effective agent from P. tenuifolia for
AD treatment. Some studies on the correlation between the
molecular structures and toxic activities of the components
suggested that removal of the oligosaccharides at C-28 by
hydrolysis will attenuate or markedly abrogate the toxic
effects [23].
But whether the hydrolysate of polygalasaponins (HPS)
has an antiamnesic effect has not been investigated. In the
present study, its effect on cognitive improvement in amnesia
C57BL/6J mice was undertaken. Amnesia was induced by
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Aβ25−35 injection into the hippocampus. Following two
behavioral tests (Morris watermaze and step-through passive
avoidance test), potential mechanisms were investigated.
2. Materials and Methods
2.1. Preparation of HPS. Air-dried root barks of P. tenuifolia
Willd were purchased from the Company of Chinese Materia
Medica in Beijing and identified by Professor Ruile Pan
from the Institute of Medicinal Plant Development, Chinese
Academy of Medical Sciences (Beijing, China). A voucher
specimen (no. 20090815) has been deposited in the Herbar-
ium of the institute. The dried roots (1 kg) were cut into
small pieces and extracted exhaustively with boiling water for
1 h four times. The filtered liquid was loaded to a column
of macroporous resin D101 (4 kg) and eluted with water,
30% ethanol, 95% ethanol successively. The 95% eluent
(enriched in saponins) was concentrated by evaporation of
the ethanol, and subsequently hydrolyzed 4 hours at pH 14
at 100◦C. After cooling, it was passed through a column of
macroporous resin D101 (4 kg) and eluted with water and
then 95% ethanol. The 95% ethanol extract was evaporated
under vacuum to yield a pale yellow residue (HPS 25 g) and
stored in a refrigerator.
2.2. Determination of HPS by HPLC. HPS was analyzed
by HPLC using Waters chromatographic equipment with
a control 600E pump, 2487UV detectors and Empower
software. HPLC conditions are as follows: a LiChroCART
C18 Column (5 μm, 250mm × 4.6mm, Merck, Darmstadt,
Germany); detection wavelength 210 nm; gradient elution
using an A eluent (MeOH) and a B eluent (0.1%, v/v, H3PO4
in water) with the following linear gradient combinations. 0
min: 30%A, 60min: 90%A. Total run time was 60min. Flow
rate was 1mL/min. The contents of tenuifolin, fallax saponin
A, 3, 4, 5-trimethoxy cinnamic acid, and p-methoxycinnamic
acid were 289.5, 197.2, 247.1, and 770mg/g, respectively.
2.3. Drugs and Reagents. Amyloid beta-Protein fragment 25–
35 (Aβ25−35) and pentobarbital sodium were from Sigma,
galantamine hydrobromide from the National Institute for
the Control of Pharmaceutical and Biological Products,
superoxide dismutase (SOD) and malondialdehyde (MDA)
kit from Nanjing Jiancheng Bioengineering Institute. All the
other reagents were analytical grade from Sigma.
2.4. Fibrillar Aβ25−35 Peptide Preparation. Aβ25−35 peptide
was dissolved in sterile saline and incubated at 37◦C for
7 days to allow fibril formation as described previously
[24]. The fibril-like structures and globular aggregates were
confirmed microscopically.
2.5. Animals. Male C57BL/6J mice (26–30 g) were pur-
chased from the Laboratory Animal Institute of the Chinese
Academy of Medical Science (qualified no.: SCXK 2004-
0001, Beijing, China). They were housed in groups of 5
animals per cage under a 12 : 12 h light-dark cycle at constant
temperature (23◦C ± 2◦C) and humidity (50%± 10%).
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Figure 1: Experimental procedure.
The animals had free access to standard chow diet and
sterilized drinking water in the SPF animal house. All
animal experiments were conducted in compliance with the
“Guide for the Care and Use of Laboratory Animals” of the
Institute ofMedicinal Plant Development (Chinese Academy
of Medical Science and Peking Union Medical College).
2.6. Apparatus. Open field, Morris water maze, and step-
through passive avoidance computer-aided controlling sys-
tems were all developed by the Institute of Medicinal Plant
Development, Chinese Academy ofMedical Sciences, and the
Chinese Astronaut Center (Beijing, China).
2.7. In Vivo Experimental Procedure. After 7 days of habit-
uation, mice were subjected to unilateral hippocampus
injection of vehicle (saline) or Aβ25−35 (1mg/mL). 24 h later,
the animals received orally either water (control, sham, and
model) or various concentrations of HPS (50 and 100mg/kg)
and galantamine (3mg/kg) for a period of 15 days. After
surgery, the mice were sequentially tested in open-field on
day 9, Morris water maze (day 10 to 13), and step-through
passive avoidance on day 15 and 16. Then, the mice were
decapitated, and the cortex and hippocampus were dissected
quickly on ice for detection of SOD activities and MDA
contents. The procedure is presented in Figure 1.
2.8. Surgical Procedure. Animals were anesthetized (ip) by
pentobarbital sodium (0.4%, 0.2mL/10 g) and positioned
in a stereotaxic frame (Benchmark Company, stereotaxic
463701, USA) for unilateral intracranial injection (right side)
of aggregated Aβ25−35 (6 μL, 1mg/mL) in the CA1 area of
the dorsal hippocampus using the coordinates derived from
the atlas of Paxinos and Franklin [25]: 2.46mm posterior
to bregma, 2.0mm lateral to the sagittal suture. These
injections (sterile saline or Aβ25−35) were made 2.0mm
beneath the surface of the skull using a microsyringe (10 μL)
equipped with a 26S-gauge needle at an infusion rate of
1 μL/min for 6mins. To avoid effusion, the needle was
removed after an additional 3min. After the injection, the
scalp was sutured and the animals were allowed to recover
from anesthesia. After the surgical procedures the mice were
randomly divided into six groups (n = 10 per group):
control, sham control, Aβ25−35 model, Aβ25−35 + positive
group (galantamine 3mg/kg/d, ig), and Aβ25−35 + HPS-
treated groups (50 and 100mg/kg/d, ig). The stereotaxic
coordinates employed are shown in Figure 2.
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Figure 2: Schema of a coronal (a) section of the mouse brain showing the microinjection sites in the hippocampus. (b) An image of the
hippocampus stained with hematoxylin and eosin stain (H&E stain). The black arrows represent the needle path and hippocampal lesions.
2.9. Open-Field Test. To verify the effects of the treatment on
locomotor activities, the animals were evaluated automati-
cally using an open field computer-aided controlling system
as described earlier [26–28]. The apparatus consists of four
metal tanks (diameter 30 cm, height 40 cm) with a video
camera fixed at the top. Experiments were performed in a
quiet room, and the apparatus was illuminated by a light
source of 120 Lux on the ceiling. Thirty minutes after drug
administration, each mouse was placed at the center of the
metal tank and allowed to explore freely for 5min and the
distance travelled in 10min, which is an index of locomotor
activities, was calculated using software. Four mice were
tested simultaneously.
2.10. Morris Water Maze Test
2.10.1. Apparatus. The apparatus is a circular water pool
(100 cm in diameter and 40 cm in height) with constant
clues external to the maze (e.g., bench, pictures, lamps,
etc.) for spatial orientation of the mice. The water was
made opaque by adding skimmed milk to prevent animals
from seeing the submerged platform. The water temperature
was kept at 24–26◦C during the experiment. An invisible
platform (6 cm diameter, 15 cm high) providing the only
escape from water was placed 1.5 cm below the water surface.
The pool was divided into four quadrants by a computerized
tracking and image analyzer system. Two principal axes of
the maze intersect perpendicularly to one another to create
an imaginary “+”. The end of each line demarcates one of the
four cardinal points: north (N), south (S), west (W), and east
(E).
2.10.2. Testing Procedure. On day 10 after surgery, theMorris
water maze paradigm was used to assess the spatial reference
memory which reflects the long-term memory ability. This
behavioral task consists of an acquisition phase and a probe
trial. The protocol was similar to that described by Morris
[29] with minor modifications [26].
In the acquisition phase, mice were submitted to daily
sessions of four trials per day for 3 days to find the submerged
platform that was located in the center of the SE quadrant
of the pool and remained at the same position throughout
the whole experiment. For each trial, the mouse was placed
for 15 sec on the platform for learning, then it was gently
released into the pool facing the wall. Four different release
points (NE, SE, SW, and NW) were varied semirandomly for
each trial. Animals were given a maximum of 60 sec to find
the platform. If the mouse failed to find the platform within
60 sec, it was gently guided to the platform and stayed there
for 10 sec and its escape latency was recorded as 60 sec. If an
animal found the platform within 60 sec, it was allowed to
remain there for 10 sec, and was then placed into a cage until
the next trial. After completion of daily training, the animals
were returned to their home cages for rest. Escape rate,
escape latency, cumulative distance, and swimming speed
were collected for subsequent analysis.
24 h later, each mouse was subjected to the retention test
(probe trial) in which the platform was removed. The mice
were released into the water on approximately the opposite
side of the SE quadrant. They were allowed to swim freely
for 60 s. The number of crossings over the position at which
the platform had been located, and the swimming time
and distance spent in the quadrant of the former platform
position were recorded as measures for spatial memory.
2.11. Passive Avoidance Test. A step-through-type passive
avoidance test was carried out to evaluate the effect of HPS
on learning and memory. The apparatus and procedure were
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the same as describe by Xue et al. [30]. The shuttle box
(60 × 50 × 80 cm) consisted of two compartments of equal
size (20×12×60 cm). Each compartment was divided into a
light and a dark chamber by a guillotine door (3×4 cm). The
light chamber was equippedwith an illuminator. All themice
were habituated to the light and dark chamber 3 times for
3 minutes until they entered the dark compartment within
15 sec (training trial). The mice that did not enter the dark
compartment within 15 sec after the 3 habituations would
be rejected. The test consisted of acquisition and retention
sessions carried out 24 and 48 hr, respectively, after the
training trial. For the acquisition trial, the mice were placed
in the illuminated chamber opposite the guillotine door and
allowed to move freely. When all four paws were on the
grid floor of the dark compartment, a scrambled constant-
current foot shock (constant voltage 50V) was delivered to
the grid. The number of times the mice stepped into the dark
chamber, the time spent in the dark chamber, and latency
to move into the dark chamber within 5 min were recorded
automatically by computer. 24 hr after the acquisition trial,
the mice were again placed in the light chamber for the
retention trial. If a mouse did not enter the dark chamber
within 300 sec, the latency was recorded as the cutoff time of
300 sec.Mice were removedmanually from the light chamber
when the cutoff time was reached.
2.12. Preparation of Brain Tissue and Homogenates. After the
final behavior test, all mice were sacrificed by decapitation.
The brains were removed immediately. For biochemical
studies, the cerebral cortex and hippocampus were dissected
on ice cubes and homogenized in 10 volumes of cold saline
using a glass homogenizer. The homogenates were cen-
trifuged at 2000 rpm for 10min at 4◦C, and the supernatants
were used for biochemical determinations.
2.13. Determination of SOD Activity and MDA Content
in Cortex and Hippocampus. Total SOD activities and
MDA levels were measured using commercial kits (Nanjing
Jiancheng Bioengineering Institute, Nanjing City, China). All
procedures complied with the manufacturer’s instructions.
The assay of total SOD was based on its ability to inhibit
the oxidation of oxymin by the xanthine-xanthine oxidase
system [31]. The activities were quantified by measuring the
amount of hydroxylamine nitrite produced by the oxidation
of oxymin. One unit (U) of SOD was defined as the amount
that reduced the absorbance at 550 nm by 50%, and data
were expressed as units per mg protein. MDA contents
were determined by the thiobarbituric acid reaction (TBAR).
A stable chromophoric product formed by reaction with
thiobarbituric acid (TBA) can be measured at the wavelength
of 532 nm [32]. MDA levels were expressed as nmoles per mg
protein. The protein concentration in the brain supernatant
was estimated using a bicinchoninic acid (BCA) kit with
bovine serum albumin as a standard at the concentration of
2mg/mL.
2.14. Data Analysis. All tests were analyzed using the SPSS
statistic 17.0 (SPSS Inc., Illinois, Chicago, USA). Data were
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Figure 3: Effect of HPS on locomotor activities of mice. Data
represent the means± SEM. n = 8–10 in each group. Gal represents
galantamine 3mg/kg group. The total distance travelled bymice was
measured after repeated administrations of HPS (50, 100mg/kg,
p.o.) for 8 days. ∗∗P < .01 compared with model group.
expressed as mean ± S.E.M (n equals the number of
mice included in each analysis). One-sample Kolmogorov-
Smirnov test was used to test data distribution. If the data
were normally distributed, the statistical evaluation of the
results was carried out using one-way analysis of variance
(ANOVA). Following significant ANOVAs, multiple post hoc
comparisons were performed using the LSD test (homoge-
neous variances) or Games-Howell test (nonhomogeneous
variances). When the data distribution was not normal, the
Kruskal-Wallis H test was used to compare the differences
between groups, and differences between pairs of medians
were analyzed using the Mann-Whitney U-test. For the
acquisition trails of Morris water maze, mean escape laten-
cies and escape rates were recorded for each day (four trials
per day), and the data were analyzed with repeated measures
and a multivariate analysis of variance (ANOVA) process
of the general linear model. The symmetry of covariance
matrices in the analyses was tested using Mauchly’s test
of sphericity. If P < .05, F-ratios were calculated using
the Greenhouse-Geisser correction. The accepted level of
significance for the tests was P < .05. Graphpad Prism
version 5.00 for Windows (GraphPad Software, San Diego
California, USA) was used for plotting.
3. Results
3.1. Effect of HPS on Locomotor Activities in the Open Field
Test. As shown in Figure 3, no significant effect of HPS
(50 and 100mg/kg, ig, 8 days) on locomotor activities
was observed in the novel environment, although the total
distance was slightly reduced in the HPS (100mg/kg) group
compared with the Aβ25−35-injected group (Games-Howell
test, P = .865). Galantamine 3mg/kg reduced the total
distance significantly compared with model groups (Games-
Howell test, P = .007).
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3.2. Effect of HPS on Spatial Reference Memory Deficits
Induced by Aβ25−35 in MWM
3.2.1. Acquisition Trails. Two-way repeated measures
ANOVA (day × group) revealed that the group had a
significant effect on the escape latency (F1,5 = 4.63, P = .002)
and escape rate (F1,5 = 5.24, P = .001). Also a significant day
effect on the escape latency (F2,41 = 49.48, P < .001) and
escape rate (F2,41 = 62.38,P < .001) was observed, which
indicated that mice improved over the course of training
trails in all groups. However, there was no significant
interaction between these two factors (day × group) in
escape latency (F10,84 = 0.48,P = .899) and escape rate
(F10,84 = 0.812,P = .618) during 3 days training. Subsequent
comparisons further suggested that no difference was
observed between the control and sham-operated groups
on escape latency (day 1, P = .805; day 2, P = .129; day 3,
P = .402) and escape rate (day 1, P = .556; day 2, P = .691;
day 3, P = .982). The mice injected with Aβ25−35 took a
longer time to locate the platform than did mice in the
sham group (Figure 4(a)), but it became significant only on
day 3 (day 1, P = .073; day 2, P = .175; day 3, P = .03).
Interestingly, when compared by the parameter escape rate
(Figure 4(b)), significant differences between model and
sham-operated groups were observed on day 1 and day
2 (day 1, P = .032; day 2, P = .031), and no significant
differences on day 3 (P = .096) when over 80% mice could
find the platform.
HPS (100mg/kg) attenuated the spatial learning deficits
observed following Aβ25−35 microinjection (10 days later),
as indicated by a reduction of the escape latency (day 1,
P = .013; day 2, P = .235; day 3, P = .032), and an
increase of escape rate (day 1, P = .017; day 2, P = .031;
day 3, P = .021) in comparison to the model group. HPS
(50mg/kg) group showed a trend, but it was not statistically
significant of decreasing the escape latency (day 1, P = .136;
day 2, P = .582; day 3, P = .347): it significantly increased the
escape rate only on day 1 (day 1, P = .032; day 2, P = .072;
day 3, P = .721). Similarly, the treatment with galantamine
(3mg/kg), a positive agent, also slightly increased the escape
rate (day 1, P = .097; day 2, P = .011; day 3, P = .089), and
reduced the escape latency (day 1, P = .108; day 2, P = .456;
day 3, P = .151) during 3 days, at least at the dose tested.
There were no significant differences in the swimming speeds
among all the groups (Figure 4(c)).
3.2.2. Probe Trail. As can be seen from Figure 5(a), the
number of platform site crossings was significantly lower in
the model mice than sham-operated mice (P < .05). Galan-
tamine (3mg/kg) slightly increased the crossing numbers
but without statistically significant difference. By contrast,
HPS (50 and 100mg/kg) increased the crossing numbers
markedly (P < .05), and the shorter swimming time in the
target quadrant induced by Aβ25−35 was significantly reversed
by HPS (50 and 100mg/kg) or galantamine (3mg/kg)
(Figure 5(b), P < .05). A similar pattern was seen for the
swimming distance in the platform quadrant (Figure 5(c)).
However, no significant differences were observed in swim-
ming speeds in the probe trail (Figure 5(d)).
3.3. Effect of HPS on Cognitive Deficits in the Step-Through
Passive Avoidance Task. One-way ANOVAs revealed a signif-
icant group effect on the acquisition trial of the step-through
test for the latency into the dark chamber (F5,50 = 12.51,
P < .001, Figure 6(a)), the time spent in the dark chamber
(F5,50 = 2.46,P = .050, Figure 6(b)), and the number of
errors (F5,50 = 3.07, P = .017, Figure 6(c)). LSD post hoc
comparison showed that the latency into the dark chamber
was significantly shorter in Aβ25−35-injected mice than that
of sham-operated mice (P < .001). Galantamine (3mg/kg)
increased the latency time significantly (P < .001), and HPS
(50 and 100mg/kg) prolonged the latency time significantly
(P < .001) in a dose-dependent manner. On the contrary,
the time spent in the dark chamber (Figure 6(b)) and the
number of errors (Figure 6(c)) were increased markedly in
the model group compared to sham group (P = .028
and .003, resp.). HPS (50 and 100mg/kg) could decrease the
time spent in dark chamber significantly (P = .028 and
P = .044). HPS (100mg/kg) and galantamine (3mg/kg)
also reduced the number of errors significantly (P = .002
and .050, resp.). However, in the consolidation trial (Figures
6(d) and 6(e)), no significant differences were observed in all
groups (Kruskal Wallis test, latency into the dark chamber:
df = 5, P = .558; number of errors: df = 5, P = .466).
3.4. Effect of HPS on SOD Activities and MDA Levels in
Cortex and Hippocampus. The difference of SOD activities
among groups was significant in the cortex (F5,51 = 5.741 =
6.967, P < .001) but not in the hippocampus (F5,51 = 1.072,
P = .387). As shown in Figure 7(a), the SOD activities
of the cortex decreased significantly in the model group
compared with the sham group (by 25.72%, P = .014).
Mice in the HPS (50 and 100mg/kg) and the galantamine
(3mg/kg) group showed higher SOD activities than mice
in the model group (by 34.47%, P = .005; 63.34%,P =
.006; 43.25%,P = .219, resp.). However, there was only
a slight increase of SOD activities in the hippocampus of
the HPS group (50mg/kg), and no difference was observed
compared with model group (by 14.78%,P > .05). On the
contrary, the MDA levels among groups were significantly
different in the hippocampus (F5,49 = 4.225,P = .003) but
not in the cortex (F5,51 = 2.852, P = .233), as shown in
Figure 7(b). The MDA levels of Aβ25−35-injected mice were
significantly higher than those of sham-operated mice in the
hippocampus (by 23.81%, P = .013), and had the same
tendency in the cortex (by 22.21%, P > .05). Galantamine
(3mg/kg) and HPS (50 and 100mg/kg) decreased the MDA
levels in the hippocampus significantly (by 16.57%, P = .027;
27.26%, P = .001; 32.35%, P < .001, resp.), and in the cortex
with a similar tendency (by 19.62%, 8.10%, and 22.57%,
resp.) without statistical difference.
4. Discussion
It is well known that Aβ deposit-induced neurotoxicity is
widely regarded as having a pivotal role in the development
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Figure 4: Effect of HPS on the acquisition of spatial reference memory in MWM task on amnesic mice induced by intra-hippocampus
Aβ25−35 microinjection. Training trials were carried out on day 9 after treatments. (a) Escape latency, (b) mean speed, and (c) escape rate of
mice to the hidden platform across the 3 days of training trials (4 trials per day). Gal 3mg/kg represents galantamine 3 mg/kg group. Values
represent mean ± S.E.M, n = 8–10 in each group. #P < .05, ##P < .01 compared with sham-operation group; ∗P < .05,∗∗P < .01 compared
with model group.
of AD [33]. Cognitive deficit has been well documented in
rodents with a centrally administered Aβ synthetic peptide,
such as Aβ1−40 [24, 31, 33–35] or Aβ1−42 [36] analogous
to peptides found in neuritic plaques in AD patients. The
peptide fragment Aβ25−35, a subset of Aβ1−42 located at the
C-terminal end in the hydrophobic domain, with only 11
amino acids, was also reported to be responsible for the
neurotoxic effect of Aβ [37, 38]. In the present study, a single
intrahippocampal injection of Aβ25−35 in C57BL/6J mice
(6 μg/mouse) did result in deficits in learning and memory.
Furthermore, these behavior deficits were accompanied by
a decrease of SOD activities and an increase of MDA levels
in the cortex and hippocampus, which is in accordance with
previous studies showing that Aβ-induced cytotoxicity is
associated with free radical oxidative stress which results in
the formation of reactive oxygen species, lipid peroxidation,
and modification of proteins by reactive lipid peroxidation
products in neurons [39–41]. These changes are similar,
at least in part, to features of the AD process. Therefore,
the Aβ25−35-injected animal model has been widely used
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Figure 5: Effect of HPS on memory retention in probe trial of MWM task on amnesic mice induced by intrahippocampal Aβ25−35
microinjection. The probe trial was performed 24 h after the acquisition phase. (a) Crossing numbers, (b) swimming time in target quadrant,
(c) swimming distance in target quadrant, and (d) swimming speed. Gal represents galantamine 3mg/kg group. Values represent mean ±
S.E.M (n = 8–10 in each group). #P < .05, ##P < .01 compared with sham operation group. ∗P < .05 compared with model group.
to evaluate the effect of anti-amnesia agents. Accordingly,
deficits produced by selective lesions of the hippocampus can
be detected by hippocampally dependent learning tasks, such
as Morris water maze [29] and inhibitory avoidance [42–44].
In our preliminary study, we found that polygalasaponins
were effective in improving learning and memory but were
also toxic to animals, leading to nose bleeding, gastrointesti-
nal tracts abnormality (hyperemia, gaseous distention, and
necrosis), and even death. Acute toxicity experiments showed
that HPS, a hydrolysate of polygalasaponins, decreased the
toxicities markedly (data not shown). The present findings
demonstrate for the first time that HPS clearly improves
cognitive deficits induced by intrahippocampal injection of
aged Aβ25−35 in mice as observed in Morris water maze
and step-through passive avoidance tests. Furthermore, the
antiamnesic effect observed here may be mediated by its
antioxidant activities.
It is important to notice that AD is associated with a
variety of hippocampus-dependent memory deficits, such as
a defect in long-term memory formation [45]. Morris water
maze is generally accepted as an indicator of spatial learning
and reference memory, which reflects long-term memory
[29, 46]. Spatial learning is assessed across repeated trials
and reference memory is determined by preference for the
platform area when the platform is absent [46]. In the present
study, we found that, between 10 and 13 days after intrahip-
pocampal injection of Aβ25−35, mice in the model group
showed significant long-term memory impairments. The
results are similar to previous studies which demonstrated
that water-maze place learning and probe trial performance
were impaired 10–14 days after i.c.v. injection of Aβ25−35
in mice [37]. The HPS (100mg/kg) significantly shortened
the escape latency prolonged by Aβ25−35 injection after 2
days of training. Interestingly, when using the escape rate
as an index of learning and memory, HPS showed strong
improving effects on all 3 days. HPS (100mg/kg) increased
the escape rate to approximately 63%, 91%, and 100% on
3 days of training, compared to that in the model group
(32%, 69%, and 84%). In addition, during the probe trial
session, HPS (50 and 100 mg/kg) increased the swimming
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Figure 6: Effect of HPS on Aβ25−35-induced memory deficits in the step-through passive avoidance test in mice. (a) Latency into the dark
chamber, (b) time spent in the dark chamber, and (c) number of errors were detected in memory acquisition stage. 24 h later, (d) latency
into the dark chamber, and (e) Number of errors were observed to assess the effect of HPS on memory consolidation. Values represent mean
± S.E.M (n = 8–10 in each group). Gal 3mg/kg represents the galantamine 3mg/kg group. #P < .05, ## P < .01, versus sham-operation
group. ∗P < .05; ∗∗P < .01, versus model group.
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Figure 7: Effect of HPS on the changes of SOD activities (a) and MDA levels (b) induced by Aβ25−35 in the cortex and hippocampus of mice.
Each value represents the mean ± S.E.M (n = 8–10 in each group). Gal 3mg/kg represents the galantamine 3mg/kg group. #P < .05, ##P <
.01, versus sham-operation group. ∗P < .05; ∗∗P < .01, versus model group.
time and distance in the quadrant where the platform was
previously placed up to 37.44% and 37.59%, respectively, as
did the galantamine-treated group. This effect was not due to
a different motor activity, because the mean swimming speed
is not significantly different among all groups. Moreover, the
model group and HPS-treated groups showed comparable
locomotor activity and emotional reactivity in the open-
field test, which can also suggest that the amelioration
was not provoked by sensorimotor effects (Figure 2). Taken
together, it is likely that HPS ameliorates the spatial reference
and long-term memory in the amnesic model induced by
Aβ25−35 intrahippocampal injection. Apart from that, an
interesting observation emerged from the results in the
Morris water maze, suggesting that different indexes had
different sensitivities to evaluate the learning and memory
abilities. Multiple index analysis may be more effective and
accurate.
To confirm the effects of HPS on other types of learning
and memory, the step-through passive avoidance task, a fear-
motivated inhibitory avoidance test indicating nonspatial
learning and memory, was performed on days 15 and 16
after surgery. The results showed that in the training trial,
latencies into the dark chamber did not vary among all
groups, indicating no difference in exploratory activity and
motor behavior induced by the treatment (data not shown).
Aβ25−35 impaired the acquisition but not the retention of
avoidance behavior in the step-through test. Giovannelli et
al. [24] similarly demonstrated memory impairments in the
step-through test in the first two weeks after intracerebral
injection of Aβ25−35, but the impairments were observed in
the retention trial and disappeared 21 days after surgery.
This discrepancy may be related to the use of one-trial
learning protocol instead of the multitrial method we used.
Treatment with HPS (50 and 100mg/kg) could ameliorate
the memory deficits significantly in the acquisition trial
(Figure 5). Besides, evidence from the inhibitory avoidance
test indicated that the aversive conditioning is learned rapidly
and fear memories tend to be very stable [44]. Gale et al. [47]
have observed that the fear response such as robust freezing
to contex lasted for 16 months following fear conditioning.
In the present study, 24 h after foot shock, mice in all groups
showed freezing and scrunching at the place away from the
dark chamber, and no difference was observed in all groups.
Galantamine, a plant alkaloid, is an acetylcholinesterase
inhibitor most commonly used to treat AD in clinics.
However, in the present study, galantamine (3mg/kg, p.o.)
showed only a slight ameliorative effect on spatial cogni-
tion in Morris water maze, which was weaker than HPS
treatment. In addition, the exploration and locomotion
activity was significantly decreased in the galantamine group.
It is congruent with previous reports that galantamine
(1.25–5.0mg/kg, i.p.) is effective in improving cognition in
several behavior tests in rodent models exhibiting cognitive
deficits [48–51], as motor activity was severely reduced [52].
Interestingly, galantamine (3mg/kg, p.o.) had a significant
improvement effect on passive avoidance behavior in the
step-through task. A potential alternative explanation of
these discrepant results in two behavior tasks may be a
difference in sensitivities of the two behavior tasks and/or
difference in the effect of galantamine on learning and mem-
ory. Clinical data have shown that galantamine improves
cognitive function and behaviour in patients who have mild
to moderate AD, but has no effect on activities of daily life
of patients with AD [53]. The present results obtained with
galantamine also indicate a limitation of acetylcholinesterase
inhibitors with regard to therapeutic usefulness for AD
patients.
Although the exact mechanisms responsible for the
cognitive impairment induced by Aβ25−35 administration in
mice are still unclear, evidence has accumulated that it may
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be related to oxidative stress [39–41, 54]. Oxidative stress
occurs when pro-oxidant and antioxidant levels become
imbalanced. SOD, as an endogenous antioxidant enzyme,
plays an important role in the intracellular antioxidant
defense in the brain. In the current study, Aβ25−35 admin-
istration led to a significant decrease of SOD activities in
the cortex (by 25.72%) but had no marked changes in the
hippocampus (by 3.66%). HPS (100mg/kg) increased the
SOD activities in the cortex significantly (by 62.34%), and to
a lesser extent (22.09%) in the hippocampus, which suggests
that HPS partially reversed the antioxidant capacity impaired
by Aβ25−35. Decreased activities of SOD further promote the
accumulation of free radicals and/or reactive oxygen species
(ROS), which initiate the oxidative damage downstream and
cause lipid peroxidation in the brain [55–57]. MDA, an
important lipid peroxidation product, can be taken as an
indicator for the state of oxidative damage of membranes
under conditions of oxidative stress. The reported abnormal
alteration in MDA content and its relation to memory
impairment have been shown in previous studies [58]. We
found that HPS (50 and 100mg/kg) decreased the MDA
levels of the hippocampus significantly, but did not change
that in the cortex obviously. The relationship between SOD
activities and MDA levels is somewhat controversial. The
difference may be related to other types of endogenous
antioxidants such as glutathione and GSH-Px [40], and
maybe they also exert the antioxidant effect simultaneously,
which needs to be further investigated.
In conclusion, the findings described in the present study
provide important information on the improvement effect
of HPS on learning and memory in an intrahippocampal-
injected Aβ25−35 mouse model. HPS not only has an
antiamnesic effect, but it also decreases the toxicities of
polygalasaponins, and may be an effective agent for AD
treatment, via antagonizing oxidative damage induced by
Aβ25−35.
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